Anti-CD163 (OR2805) is a human monoclonal antibody of the IgG1 subclass designed to specifically target CD163, also known as scavenger receptor cysteine-rich type 1 protein M130. This antibody exhibits potential immunomodulating and antineoplastic properties by selectively binding to CD163, which is prominently expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME). By binding to CD163, Anti-CD163 (OR2805) effectively inhibits the interaction of CD163 with its natural ligands, thereby modulating the immunosuppressive activity of TAMs and potentially enhancing antitumor immune responses. This mechanism positions Anti-CD163 (OR2805) as a valuable tool for research in cancer immunology and therapeutic development.
Anti-CD163 (OR2805) is a human monoclonal antibody of the IgG1 subclass designed to specifically target CD163, also known as scavenger receptor cysteine-rich type 1 protein M130. This antibody exhibits potential immunomodulating and antineoplastic properties by selectively binding to CD163, which is prominently expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME). By binding to CD163, Anti-CD163 (OR2805) effectively inhibits the interaction of CD163 with its natural ligands, thereby modulating the immunosuppressive activity of TAMs and potentially enhancing antitumor immune responses. This mechanism positions Anti-CD163 (OR2805) as a valuable tool for research in cancer immunology and therapeutic development.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
